Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera
Protagonist Therapeutics Inc. (NASDAQ:PTGX) is one of the best mid cap growth stocks to invest in now.
Protagonist Therapeutics Inc (PTGX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 6,107,006 | $295,334,810 | +3% | 1.65% |
| 2. | Deep Track Capital David Kroin | 3,000,000 | $145,080,000 | +200% | 4.7% |
| 3. | Biotechnology Value Fund / BVF Inc Mark Lampert | 2,575,015 | $124,527,725 | +36% | 5.08% |
| 4. | Perceptive Advisors Joseph Edelman | 1,091,271 | $52,773,866 | -15% | 1.86% |
| 5. | ADAR1 Capital Management Daniel Schneeberger | 939,669 | $45,442,393 | -8% | 8.44% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.70 | 12,000 | $80,400.00 | 15,310 | 2020-03-12 | Filing | |
| $5.70 | 8,000 | $45,620.00 | 8,000 | 2019-12-03 | Filing | |
| $5.13 | 30,000 | $153,900.00 | 49,500 | 2019-12-03 | Filing | |
| $5.09 | 562 | $2,860.58 | 1,175 | 2019-12-03 | Filing | |
| $5.10 | 613 | $3,126.30 | 613 | 2019-12-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $57.03 | 10,000 | $570,300.00 | 83,892 | 2025-06-10 | Filing | |
| $55.51 | 10,000 | $555,100.00 | 83,892 | 2025-06-09 | Filing | |
| $46.00 | 1,756 | $80,776.00 | 61,065 | 2025-04-22 | Filing | |
| $54.25 | 4,000 | $217,000.00 | 13,130 | 2025-03-17 | Filing | |
| $55.74 | 30,514 | $1,700,850.36 | 83,892 | 2025-03-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,736,767 | $470,870,063 | 0.01% | |
| 2. | 5,719,415 | $276,590,909 | 4.23% | |
| 3. | 4,277,218 | $206,846,263 | 0% | |
| 4. | 2,706,619 | $130,892,095 | 0.01% | |
| 5. | 2,449,183 | $118,442,490 | 34.65% |
News See All
11 Best Mid Cap Growth Stocks To Invest In Now
On June 18, Scott Wren, Wells Fargo senior global market strategist, joined CNBC's 'Closing Bell Overtime' to talk about how the market sell-off is an opportunity to step in.
Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is one of the 10 biotech stocks screaming a buy. On June 17, Citi initiated coverage of the stock with a ‘Buy’ rating and a $72 price target.
10 Biotech Stocks Screaming a Buy
The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott, given the 10% year-to-date loss by the SPDR S&P Biotech ETF.
Protagonist Therapeutics (PTGX) Rose on Positive Trial Outcome
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
10 Best Cancer Stocks to Invest in for Long-Term Gains
After cardiovascular disease, cancer is the second most common cause of mortality worldwide.
Top 10 Trending Stocks as AI Hype Fades
The US stock market took a major hit recently due to tariff-related uncertainties and a broader concern about AI stock valuations.
10 Best Healthcare Stocks For Long-Term Investment
In the US, healthcare expenditures and costs have been increasing. According to the Centers for Medicare & Medicaid Services, US healthcare spending increased 7.5% from 2022 to $4.9 trillion in 2023.
10 Cheap Biotech Stocks to Invest in Now
Biotechnology stocks are among the most volatile in the market due to their high risk.
8 High Growth High Margin Stocks to Invest In Now
When investor confidence is high, capital tends to flow into growth sectors, driving up stock prices and valuations.